Truist raised the firm’s price target on Exelixis (EXEL) to $42 from $38 and keeps a Buy rating on the shares after its positive Q4 pre-announcement. The firm views the stock favorably, and even with the recent stock gain, there is more opportunity for shares to gain, the analyst tells investors in a research note. Zanza – the “son of Cabometyx – also has potentially value inflecting points in 2025 that could push the firm’s price target higher, Truist adds, stating that despite the “choppy” biotech, Exelixis is a “very investable name in 2025”.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $41 from $34 at JMP Securities
- Exelixis price target raised to $37 from $36 at Piper Sandler
- Exelixis reports preliminary FY24 revenue $2.165B, consensus $2.16B
- Exelixis price target raised to $40 from $29 at H.C. Wainwright
- No FDA advisory meeting for Exelixis a positive, says Citi